Rhonda F. Farnum is the Chief Business Officer and Senior Vice President, Commercial & Medical Affairs at Theravance Biopharma Inc., a biopharmaceutical company focused on developing respiratory and infectious disease therapies. In her dual role, she leads strategic business development, commercial operations, and medical affairs, overseeing partnerships, market access strategies, and the advancement of the company's pipeline, including key assets like revefenacin (Yupelri®) and treprostinil inhalation solution (Tyvaso DPI®). Her leadership has been pivotal in driving Theravance's growth through innovative collaborations and commercialization efforts in competitive therapeutic areas. With over 25 years of experience in the biopharmaceutical industry, Rhonda previously served as Vice President of US Respiratory Brands at GlaxoSmithKline (GSK), where she spearheaded the commercial strategy for blockbuster inhalers such as Advair, Breo Ellipta, and Anoro Ellipta, achieving significant market expansion and revenue growth exceeding $5 billion annually. Earlier in her career, she held progressive roles at Purdue Pharma and Wyeth (now Pfizer), honing her expertise in respiratory medicine, sales leadership, and regulatory strategy. Her accomplishments include launching multiple FDA-approved products and forging strategic alliances that accelerated market entry. Rhonda's strategic vision and deep industry knowledge have positioned Theravance Biopharma for sustained success, including successful nebulized product launches and ongoing preparations for next-generation therapies. A graduate of the University of California, Davis, with a degree in Biological Sciences, she is a recognized leader in biotech commercial affairs and serves on industry advisory boards dedicated to advancing respiratory care.